Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study
Takashi Ishida, Tatsuro Joh, Naokuni Uike, et al.
Journal of Clinical Oncology (2012) Vol. 30, Iss. 8, pp. 837-842
Open Access | Times Cited: 619

Showing 1-25 of 619 citing articles:

Glycosylation in health and disease
Colin Reily, Tyler J. Stewart, Matthew B. Renfrow, et al.
Nature Reviews Nephrology (2019) Vol. 15, Iss. 6, pp. 346-366
Open Access | Times Cited: 1613
International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors
Françoise Bachelerie, Adit Ben‐Baruch, Amanda M. Burkhardt, et al.
Pharmacological Reviews (2013) Vol. 66, Iss. 1, pp. 1-79
Open Access | Times Cited: 798
Monoclonal Antibodies in Cancer Therapy
David J. Zahavi, Louis M. Weiner
Antibodies (2020) Vol. 9, Iss. 3, pp. 34-34
Open Access | Times Cited: 611
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama, Hiroyoshi Nishikawa, Yuka Maeda, et al.
Proceedings of the National Academy of Sciences (2013) Vol. 110, Iss. 44, pp. 17945-17950
Open Access | Times Cited: 583
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting
Belal Chaudhary, Eyad Elkord
Vaccines (2016) Vol. 4, Iss. 3, pp. 28-28
Open Access | Times Cited: 435
CCR4 and its ligands: from bench to bedside
Osamu Yoshie, Kouji Matsushima
International Immunology (2014) Vol. 27, Iss. 1, pp. 11-20
Open Access | Times Cited: 360
Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Michinori Ogura, Takashi Ishida, Kiyohiko Hatake, et al.
Journal of Clinical Oncology (2014) Vol. 32, Iss. 11, pp. 1157-1163
Open Access | Times Cited: 337
Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma
Kenji Ishitsuka, Kazuo Tamura
The Lancet Oncology (2014) Vol. 15, Iss. 11, pp. e517-e526
Closed Access | Times Cited: 318
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
Stephen Bagley, Arati Desai, Gerald P. Linette, et al.
Neuro-Oncology (2018) Vol. 20, Iss. 11, pp. 1429-1438
Open Access | Times Cited: 261
Nanomaterials for cancer immunotherapy
Wantong Song, Sara Musetti, Leaf Huang
Biomaterials (2017) Vol. 148, pp. 16-30
Open Access | Times Cited: 252
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
Shahneen Sandhu, K. Papadopoulos, Peter C.C. Fong, et al.
Cancer Chemotherapy and Pharmacology (2013) Vol. 71, Iss. 4, pp. 1041-1050
Closed Access | Times Cited: 244
Adult T-Cell Leukemia: A Review of Epidemiological Evidence
Masako Iwanaga, Toshiki Watanabe, Kazunari Yamaguchi
Frontiers in Microbiology (2012) Vol. 3
Open Access | Times Cited: 236
Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study
Takashi Ishida, Tatsuro Jo, Shigeki Takemoto, et al.
British Journal of Haematology (2015) Vol. 169, Iss. 5, pp. 672-682
Open Access | Times Cited: 236
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma
Madeleine Duvic, Lauren Pinter‐Brown, Francine M. Foss, et al.
Blood (2015) Vol. 125, Iss. 12, pp. 1883-1889
Open Access | Times Cited: 215
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
Josée Golay, Fabio Da Roit, Luca Bologna, et al.
Blood (2013) Vol. 122, Iss. 20, pp. 3482-3491
Open Access | Times Cited: 211
Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report
Lucy Cook, Shigeo Fuji, Olivier Hermine, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 8, pp. 677-687
Open Access | Times Cited: 208
Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
Koji Kurose, Yoshihiro Ohue, Hisashi Wada, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 19, pp. 4327-4336
Open Access | Times Cited: 206
Targeting regulatory T cells in tumors
Chang Liu, Creg J. Workman, Dario A.A. Vignali
FEBS Journal (2016) Vol. 283, Iss. 14, pp. 2731-2748
Open Access | Times Cited: 205
The Use of Lentinan for Treating Gastric Cancer
Kenji Ina, Takae Kataoka, Takafumi Ando
Anti-Cancer Agents in Medicinal Chemistry (2013) Vol. 13, Iss. 5, pp. 681-688
Open Access | Times Cited: 201
Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy
Yusuke Mimura, Toshihiko Katoh, Radka Saldova, et al.
Protein & Cell (2017) Vol. 9, Iss. 1, pp. 47-62
Open Access | Times Cited: 190
Viral Oncology: Molecular Biology and Pathogenesis
Uyen Ngoc Mui, Christopher T. Haley, Stephen K. Tyring
Journal of Clinical Medicine (2017) Vol. 6, Iss. 12, pp. 111-111
Open Access | Times Cited: 188
Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy
Haiping Wang, Fabien Franco, Ping‐Chih Ho
Trends in cancer (2017) Vol. 3, Iss. 8, pp. 583-592
Closed Access | Times Cited: 184
Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
Catherine J. Hutchings, Markus Koglin, William C. Olson, et al.
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 11, pp. 787-810
Closed Access | Times Cited: 180
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Sachin S. Shivatare, Vidya S. Shivatare, Chi‐Huey Wong
Chemical Reviews (2022) Vol. 122, Iss. 20, pp. 15603-15671
Open Access | Times Cited: 107
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
Koji Izutsu, Shinichi Makita, Kisato Nosaka, et al.
Blood (2022) Vol. 141, Iss. 10, pp. 1159-1168
Open Access | Times Cited: 95
Page 1 - Next Page

Scroll to top